

Daniel A Laheru

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/787656/publications.pdf>

Version: 2024-02-01

80
papers

12,357
citations

101543

36
h-index

82547

72
g-index

80
all docs

80
docs citations

80
times ranked

15519
citing authors

#	ARTICLE	IF	CITATIONS
1	Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 401-414.	1.5	11
2	Endoplasmic stressâ€inducing variants in <i>CPB1</i> and <i>CPA1</i> and risk of pancreatic cancer: A caseâ€control study and metaâ€analysis. <i>International Journal of Cancer</i> , 2022, 150, 1123-1133.	5.1	11
3	Calciophylaxis Cutis Associated With Fibroblast Growth Factor Receptor (FGFR) Inhibitor Therapy: A New Challenge. <i>Cureus</i> , 2022, 14, e21478.	0.5	1
4	Neoadjuvant and adjuvant antitumor vaccination alone or combination with PD1 blockade and CD137 agonism in patients with resectable pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 558-558.	1.6	7
5	Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity. <i>Annals of Surgical Oncology</i> , 2022, 29, 2456-2468.	1.5	12
6	High local failure rates despite high marginâ€negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multiâ€agent chemotherapy. <i>Cancer Medicine</i> , 2022, , .	2.8	11
7	Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial. <i>Practical Radiation Oncology</i> , 2022, 12, 511-523.	2.1	5
8	RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. <i>JCO Precision Oncology</i> , 2022, , .	3.0	1
9	Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. <i>Cancer Letters</i> , 2021, 497, 221-228.	7.2	10
10	Survival Outcomes of Adjuvant Chemotherapy Combined With Radiation Versus Chemotherapy Alone After Pancreatectomy for Distal Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2021, 50, 64-70.	1.1	0
11	Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4574-4586.	7.0	82
12	Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity. <i>Nature Cancer</i> , 2021, 2, 891-903.	13.2	147
13	From bench to bedside: Single-cell analysis for cancer immunotherapy. <i>Cancer Cell</i> , 2021, 39, 1062-1080.	16.8	67
14	Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer. <i>Pancreatology</i> , 2021, 21, 938-941.	1.1	1
15	Projected 30- day out-of-pocket costs and total spending on pancreatic enzyme replacement therapy under Medicare Part D. <i>Pancreatology</i> , 2021, 21, 1009-1010.	1.1	6
16	ASO Visual Abstract: Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 714-715.	1.5	1
17	Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells. <i>Cancer Biology and Medicine</i> , 2021, 18, 206-214.	3.0	18
18	Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1278-1286.	7.0	35

#	ARTICLE	IF	CITATIONS
19	A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. <i>Cancer Medicine</i> , 2020, 9, 1485-1494.	2.8	48
20	Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma. <i>Journal of the American College of Surgeons</i> , 2020, 231, 527-535.e14.	0.5	11
21	Metastatic Pancreatic Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 3217-3230.	1.6	151
22	Intraductal pancreatic cancer is less responsive than cancer in the stroma to neoadjuvant chemotherapy. <i>Modern Pathology</i> , 2020, 33, 2026-2034.	5.5	9
23	A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5129-5139.	7.0	67
24	Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis. <i>Clinical Cancer Research</i> , 2020, 26, 4842-4851.	7.0	72
25	Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3578-3588.	7.0	76
26	An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma. <i>Oncotarget</i> , 2020, 11, 1929-1941.	1.8	7
27	Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4973-4984.	7.0	118
28	Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival. <i>Cancer Immunology Research</i> , 2019, 7, 886-895.	3.4	171
29	Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 557-567.	6.3	21
30	Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 112-121.	1.7	54
31	Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. <i>Annals of Surgery</i> , 2019, 270, 340-347.	4.2	280
32	PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. <i>JCI Insight</i> , 2019, 4, .	5.0	345
33	Assessment of iodine uptake by pancreatic cancer following chemotherapy using dual-energy CT. <i>Abdominal Radiology</i> , 2018, 43, 445-456.	2.1	19
34	Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?. <i>Annals of Surgery</i> , 2018, 268, 1-8.	4.2	139
35	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nature Communications</i> , 2018, 9, 556.	12.8	188
36	Assessing the Financial Burden Associated With Treatment Options for Resectable Pancreatic Cancer. <i>Annals of Surgery</i> , 2018, 267, 544-551.	4.2	14

#	ARTICLE	IF	CITATIONS
37	Long-term analysis of 2 prospective studies that incorporate mitomycin C into an adjuvant chemoradiation regimen for pancreatic and periampullary cancers. <i>Advances in Radiation Oncology</i> , 2018, 3, 42-51.	1.2	2
38	Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 486-489.	0.8	2
39	Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective. <i>Annals of Surgical Oncology</i> , 2018, 25, 280-289.	1.5	31
40	T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. <i>JCI Insight</i> , 2018, 3, .	5.0	206
41	A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan. <i>Clinical Cancer Research</i> , 2018, 24, 6160-6167.	7.0	46
42	Stereotactic body radiation therapy for palliative management of pancreatic adenocarcinoma in elderly and medically inoperable patients. <i>Oncotarget</i> , 2018, 9, 16427-16436.	1.8	28
43	A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. <i>British Journal of Cancer</i> , 2017, 116, 575-583.	6.4	73
44	Strategies for Increasing Pancreatic Tumor Immunogenicity. <i>Clinical Cancer Research</i> , 2017, 23, 1656-1669.	7.0	131
45	Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. <i>Cancer Medicine</i> , 2017, 6, 1552-1562.	2.8	19
46	The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA. <i>Clinical Cancer Research</i> , 2017, 23, 2471-2477.	7.0	154
47	Reply to A. Wang-Gillam et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 690-691.	1.6	0
48	Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2017, 13, 261-264.	2.5	26
49	The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma. <i>PLoS ONE</i> , 2017, 12, e0180181.	2.5	68
50	Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer. <i>Practical Radiation Oncology</i> , 2016, 6, 417-424.	2.1	19
51	Metastatic pancreatic adenocarcinoma associated with chronic calcific pancreatitis and a heterozygous SPINK1 N34S mutation. <i>Pancreatology</i> , 2016, 16, 869-872.	1.1	3
52	A Polycythemia Vera/JAK2 Mutation Masquerading as a Duodenal Cancer Mutation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1495-1498.	4.9	12
53	Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 571-579.	0.8	172
54	Multidisciplinary management and the future of treatment in cholangiocarcinoma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 255-267.	0.8	2

#	ARTICLE	IF	CITATIONS
55	Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer. <i>Cancer Immunology Research</i> , 2016, 4, 225-233.	3.4	21
56	Evaluation of low-dose fractionated radiation therapy as a chemopotentiator of gemcitabine in advanced pancreatic cancer: results from an international multi-institutional phase II trial. <i>Journal of Radiation Oncology</i> , 2015, 4, 401-409.	0.7	0
57	Correlation of Clinical Stage and Performance Status With Quality of Life in Patients Seen in a Pancreas Multidisciplinary Clinic. <i>Journal of Oncology Practice</i> , 2015, 11, e216-e221.	2.5	36
58	Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 489-498.	2.3	59
59	Safety and Survival With GVAX Pancreas Prime and <i>Listeria Monocytogenes</i> Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1325-1333.	1.6	490
60	PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors. <i>Journal of Immunotherapy</i> , 2015, 38, 1-11.	2.4	333
61	Resected pancreatic ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns. <i>Oncotarget</i> , 2015, 6, 36903-36910.	1.8	62
62	Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 115-25.	1.4	22
63	Baseline Metabolic Tumor Volume and Total Lesion Glycolysis Are Associated With Survival Outcomes in Patients With Locally Advanced Pancreatic Cancer Receiving Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 539-546.	0.8	70
64	Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation. <i>Cancer Immunology Research</i> , 2014, 2, 616-631.	3.4	408
65	Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas.. <i>Journal of Clinical Oncology</i> , 2014, 32, 269-269.	1.6	15
66	Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. <i>New England Journal of Medicine</i> , 2013, 369, 1691-1703.	27.0	5,097
67	Role of radiotherapy in combination with chemotherapy, targeted therapy, and immunotherapy in the management of pancreatic cancer. <i>Journal of Radiation Oncology</i> , 2013, 2, 369-379.	0.7	3
68	Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relationships. <i>Journal of Radiation Oncology</i> , 2013, 2, 413-425.	0.7	74
69	Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer. <i>Journal of Immunotherapy</i> , 2013, 36, 382-389.	2.4	460
70	Recent progress in pancreatic cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2013, 63, 318-348.	329.8	743
71	Prognostic factors for achieving resection following neoadjuvant radiation therapy for borderline resectable pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 285-285.	1.6	0
72	Hemoglobin-A1c level to predict for clinical outcomes in patients with pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4039-4039.	1.6	1

#	ARTICLE	IF	CITATIONS
73	Chemotherapy-induced diarrhea in older patients with colorectal cancer receiving fluoropyrimidines: A retrospective review.. Journal of Clinical Oncology, 2013, 31, e14647-e14647.	1.6	0
74	Is successful resection following neoadjuvant radiation therapy for borderline resectable pancreatic cancer dependent on improved tumor-vessel relationships?. Journal of Clinical Oncology, 2013, 31, 4057-4057.	1.6	1
75	A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction. Clinical Cancer Research, 2012, 18, 858-868.	7.0	304
76	Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 622	2.6	92
77	Patient retention and costs associated with a pancreatic multidisciplinary clinic.. Journal of Clinical Oncology, 2012, 30, 96-96.	1.6	0
78	Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients. Journal of Experimental Medicine, 2004, 200, 297-306.	8.5	314
79	Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factorâ€™Secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation. Journal of Clinical Oncology, 2001, 19, 145-156.	1.6	542
80	Primary Pancreatic Adenocarcinoma. , 0, , 498-542.		0